Pharmacoeconomic spotlight on varenicline as an aid to smoking cessation

CNS Drugs

Volumn 24, Issue 9, 2010, Pages 797-800

  Keating, Gillian M ^a   Lyseng Williamson, Katherine A ^a  

^a Wolters Kluwer Health   (New Zealand)

Author keywords

Adis Spotlights; Cholinergic receptor agonists; Smoking cessation therapies; Smoking withdrawal; therapeutic use; Varenicline

Indexed keywords

AMFEBUTAMONE; NICOTINE; NORTRIPTYLINE; VARENICLINE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG CHOICE; DRUG COST; DRUG SAFETY; HUMAN; NAUSEA; NICOTINE REPLACEMENT THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SMOKING CESSATION; SMOKING CESSATION PROGRAM; TOBACCO DEPENDENCE;

BENZAZEPINES; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; NICOTINIC AGONISTS; QUINOXALINES; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 77956204124     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11204710-000000000-00000     Document Type: Review

References (38)

1. Keating GM, Lyseng-Williamson KA. Varenicline: a phar-macoeconomic review of its use as an aid to smoking cessation. Pharmacoeconomics 2010; 28 (3): 231-254
2. Guindon GE, Boisclair D. Past, current and future trends in tobacco use [online]. Available from URL: http://www1. worldbank.org/tobacco/pdf/Guindon- Past,%20current-%20 whole.pdf [Accessed 2009 Sep 24]
3. Smoking-attributable mortality, years of potential life lost, and productivity losses: United States, 2000-2004. MMWR Morb Mortal Wkly Rep 2008 Nov 14; 57 (45): 1226-1228
4. Stack NM. Smoking cessation: an overview of treatment options with a focus on varenicline. Pharmacotherapy 2007 Nov; 27 (11): 1550-1557
5. Ezzati M, Lopez AD. Regional, disease specific patterns of smoking-attributable mortality in 2000. Tob Control 2004 Dec; 13 (4): 388-395
6. Armour BS, Finkelstein EA, Fiebelkorn IC. State-level Medicaid expenditures attributable to smoking. Prev Chronic Dis 2009 Jul; 6 (3): 1-10
7. World Health Organization. The European tobacco control report 2007 [online]. Available from URL: http://www.euro. who.int/document/e89842.pdf [Accessed 2009 Sep 24]
8. Menzin J, Lines LM, Marton J. Estimating the short-term clinical and economic benefits of smoking cessation: do we have it right? Expert Rev Pharmacoecon Outcomes Res 2009 Jun; 9 (3): 257-264
9. Hays JT, Ebbert JO, Sood A. Efficacy and safety of varenicline for smoking cessation. Am J Med 2008 Apr; 121 (4 Suppl. 1): S32-42
10. Edwards R. ABC of smoking cessation: the problem of to-bacco smoking. BMJ 2004 Jan 24; 328 (7433): 217-219
11. Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update [online]. Available from URL: http://www.surgeongeneral.gov/tobacco/ treating-tobacco- use08.pdf [Accessed 2009 Sep 15]
12. Galanti LM. Tobacco smoking cessation management: integrating varenicline in current practice. Vasc Health Risk Manag 2008; 4 (4): 837-845
13. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006 Jul 5; 296 (1): 47-55
14. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of vare-nicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006 Jul 5; 296 (1): 56-63
15. Nakamura M, Oshima A, Fujimoto Y, et al. Efficacy and tolerability of varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007 Jun; 29 (6): 1040-1056
16. Aubin H-J, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008 Aug; 63 (8): 717-724
17. Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006 Jul 5; 296 (1): 64-71
18. Nides M, Glover ED, Reus VI, et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav 2008 Nov-Dec; 32 (6): 664-675
19. Pfizer Inc. Chantix® (varenicline) tablets: US prescribing in-formation [online]. Available from URL: http://media.pfizer. com/files/products/uspi-chantix.pdf [Accessed 2009 Sep 15]
20. Howard P, Knight C, Boler A, et al. Cost-utility analysis of var-enicline versus existing smoking cessation strategies using the BENESCO simulation model: application to a population of US adult smokers. Pharmacoeconomics 2008; 26 (6): 497-511
21. Annemans L, Nackaerts K, Bartsch P, et al. Cost effective-ness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis. Clin Drug Invest 2009; 29 (10): 655-665
22. Hoogendoorn M, Welsing P, Rutten-van Molken MPMH. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin 2008 Jan; 24 (1): 51-61
23. Narvaez J, Alvis N, de La Hoz F, et al. An economic eval-uation of a pharmacological intervention using varenicline as therapy for smoking cessation [abstract no. PRS16]. Value Health 2009 May; 12 (3): A123
24. O'Regan CP, Baker CL, Marchant N. The cost-effectiveness of the novel prescription therapy varenicline in Scotland [abstract no. RPOS3-45 plus poster]. 13th Annual Meeting of the Society for the Research on Nicotine and Tobacco; 2007 Feb 21-24; Austin (TX
25. Skoupa J, Dolezal T, Hajek P, et al. Long-term cost-effectiveness analysis of varenicline versus nicotine replacement therapy, bupropion, and unaided cessation for smoking cessation in the Czech Republic [abstract plus poster]. 10th Annual Meeting of the Society for Research on Nicotine and Tobacco Europe; 2008 Sep 23-26; Rome
26. Poulsen PB, Dollerup J, Keiding H. The cost-effectiveness of varenicline in smoking cessation in Denmark [abstract plus poster]. International Society for Pharmacoeconomics and Outcomes Research 11th Annual European Congress; 2008 Nov 8-11; Athens
27. Rasch A, Greiner W. Gesundheitsokonomisches Modell der Raucherentwohnung mit Vareniclin. Suchtmed Forsch Prax 2009 Sep; 11 (2): 47-55
28. Fernandez de Bobadilla Osorio J, Sanchez-Maestre C, Brosa Riestra M. Cost effectiveness analysis of varenicline (Champix®) for the treatment of smoking in Spain [in Spanish]. An Med Interna 2008; 25 (7): 342-348
29. Bolin K, Mork A-C, Willers S, et al. Varenicline as compared to bupropion in smoking-cessation therapy: cost-utility results for Sweden 2003. Respir Med 2008 May; 102 (5): 699-710
30. Lee KK, Lee VWY, Chow DP. Cost effectiveness of vare-nicline compared with existing smoking cessation strategies in Hong Kong [abstract no. PRS16]. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2009 Oct 24-29; Paris
31. Linden K, Jormanainen V, Linna M, et al. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers. Curr Med Res Opin 2010 Mar; 26 (3): 549-560
32. Linden K, Kotomaki T, Wilson K. Cost-effectiveness of varenicline versus nicotine replacement therapy for smoking cessation in Finland [abstract plus poster]. 10th Annual Meeting of the Society for Research on Nicotine and Tobacco Europe; 2008 Sep 23-26; Rome
33. Mould-Quevedo JF, Contreras-Hernandez I. Analisis coste-efectividad de vareniclina (Champix®) frente a los parches de nicotina en el tratamiento del tabaquismo en Mexico. Pharmacoeconomics Span Res Articles 2009; 6 (1): 22-32
34. Bolin K, Wilson K, Benhaddi H. Cost-effectiveness of vare-nicline compared with nicotine patches for smoking cessation: results from four European countries. Eur J Public Health 2009 Dec; 19 (6): 650-654
35. Bolin K, Mork A-C, Wilson K. Smoking-cessation therapy using varenicline: the cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence. J Eval Clin Pract 2009 Jun; 15 (3): 478-485
36. Knight C, Howard P, Baker CL, et al. The cost-effectiveness of an extended course (12+ 12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model. Value Health. Epub 2009 Nov 13
37. Igarashi A, Takuma H, Fukuda T, et al. Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan. Pharmacoeconomics 2009; 27 (3): 247-261
38. Halpern MT, Dirani R, Schmier JK. The cost effectiveness of varenicline for smoking cessation. Manag Care Interface 2007 Oct; 20 (10): 18-25